Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Associate Safety Director (m/f/d) (LSW)- Drug safety/pharmacovigilance/ English Background: Portfolio Safety Scientists (PCS-Sci) provide safety science and pharmacovigilance support to molecules across the Roche portfolio. As a group, they are responsible for all aspects of safety
RhyGaze is a biotech company developing transformative gene therapies to restore vision in patients with blindness. Our programs target patients with blinding retinal diseases, and we are committed to bringing life-changing treatments to those in need.
Innovative Biopharmaceutical Company | Northwestern Switzerland Shape the Global Regulatory Strategy for Innovative Small Molecule Therapies Our client is an innovative, research-driven biotechnology company advancing a portfolio of novel small molecule therapies through late-stage clinical development.
RhyGaze is a biotech company developing transformative gene therapies to restore vision in patients with blindness. Our programs target patients with blinding retinal diseases, and we are committed to bringing life‑changing treatments to those in need.
gloor&lang AG in Basel seeks a senior Regulatory Affairs CMC expert to lead global CMC strategy for development and registration of small molecule therapies, shaping regulatory submissions (Module 3) and lifecycle management in collaboration with CMC
Innovative Biopharmaceutical Company | Northwestern SwitzerlandShape the Global Regulatory Strategy for Innovative Small Molecule TherapiesOur client is an innovative, research-driven biotechnology company advancing a portfolio of novel small molecule therapies through late-stage clinical development.As the organization